Alto Neuroscience posts investor presentation outlining precision psychiatry pipeline, biomarker-driven drug strategy

Alto Neuroscience, Inc.

Alto Neuroscience, Inc.

ANRO

0.00
  • Alto Neuroscience outlined a biomarker-driven precision psychiatry strategy to target responsive patient groups earlier in development.
  • ALTO-207 for treatment-resistant depression: Phase 2b ongoing; Phase 3 initiation planned by early 2027; Phase 2b topline data expected in 2H 2027.
  • ALTO-300 for major depressive disorder: Phase 2b ongoing; topline data expected in 1H 2027; ALTO-208 bipolar depression readout targeted for mid-2027.
  • Company forecast an expected cash runway through 2029; highlighted four late-stage data readouts over the next about three years.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.